Drug – bio-affecting and body treating compositions – Solid synthetic organic polymer as designated organic active...
Reexamination Certificate
1997-07-01
2001-03-06
Kulkosky, Peter F. (Department: 1615)
Drug, bio-affecting and body treating compositions
Solid synthetic organic polymer as designated organic active...
C604S005010
Reexamination Certificate
active
06197289
ABSTRACT:
BACKGROUND OF THE INVENTION
The invention relates to removing biologically active agents from liquids.
At times it is necessary to remove biologically active agents from liquids such as body fluids. Heparin, for example, is routinely added to blood as an anticoagulant in applications where the blood is to be transferred through extracorporeal circuits such as those employed in hemodialysis and cardiovascular surgery. The presence of heparin in the blood, however, creates a significant risk of hemorrhaging. Thus, it is highly desirable to remove excess heparin from blood when it is no longer desirable for the blood to have anticoagulating properties.
SUMMARY OF THE INVENTION
In one aspect, the invention features an apparatus for removing a biologically active agent (e.g., heparin) from body fluid that includes an inlet for receiving body fluid, a substrate that includes the reaction product of a substantially water insoluble polymer and a polyalkylene imine, the polyalkylene imine being in a form capable of binding a biologically active agent in the body fluid, and an outlet through which the body fluid flows following contact with the substrate. The invention also features a method for removing a biologically active agent from body fluid using this apparatus.
Biologically active agents which can be removed include negatively charged materials. Specific examples of biologically active agents that can be removed include heparin, heparan sulfate, hyaluronic acid, dermatan sulfate, chitosan, derivatives thereof, and combinations thereof.
The preferred polyalkylene imine is polyethylene imine. Preferred substantially water insoluble polymers include functional groups such as ester groups that are capable of forming a covalent bond with the polyalkylene imine. Specific examples include (a) the reaction product of an alkyl acrylate and an alkyl methacrylate, b) the reaction product of an alkyl acrylate, an alkyl methacrylate, and a hydroxy alkyl acrylate, and (c) the reaction product of an alkyl methacrylate, an alkyl acrylate, and N-vinyl pyrrolidone (e.g., the reaction product of methyl methacrylate, isooctyl acrylate, and N-vinyl pyrrolidone). The acrylate, methacrylate, and N-vinyl pyrrolidone may be provided in the form of monomers, oligomers, or a combination thereof.
In one preferred embodiment, the apparatus further includes a conduit for transporting body fluid from a patient to the inlet and a conduit for transporting body fluid through the outlet to a patient. In one embodiment, the apparatus is in fluid communication with a blood oxygenator. In another embodiment, the apparatus is in fluid communication with a blood dialyzer. The apparatus may also be in the form of a syringe.
In a second aspect, the invention features an apparatus for removing a biologically active agent from body fluid that includes an inlet for receiving body fluid, a substrate that includes a polyalkylene imine immobilized thereon in a form capable of binding the biologically active agent, and an outlet through which the body fluid flows following contact with the substrate. The invention also features a method for removing a biologically active agent from body fluid using this apparatus.
Throughout this application the following definitions apply:
A “biologically active agent” is a material that, when in contact with a patient's blood, plasma, or other body fluids or tissues under physiological conditions, exhibits biological activity. For instance, a material such as heparin is “biologically active” in the sense that it acts as an anti-coagulant in the presence of blood.
The invention provides a simple and effective means for removing biologically active agents such as heparin from body fluid. The process may be conducted in the presence of red blood cells.
Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.
REFERENCES:
patent: 2016962 (1935-10-01), Flint et al.
patent: 2918462 (1959-12-01), Druey et al.
patent: 3096602 (1963-07-01), Newmaker, Jr.
patent: 3453194 (1969-07-01), Bennett et al.
patent: 3475358 (1969-10-01), Bixler et al.
patent: 3475410 (1969-10-01), Britton
patent: 3616935 (1971-11-01), Love et al.
patent: 3617344 (1971-11-01), Leininger et al.
patent: 3634123 (1972-01-01), Eriksson et al.
patent: 3639141 (1972-02-01), Dyck
patent: 3673612 (1972-07-01), Merrill et al.
patent: 3755218 (1973-08-01), Yen et al.
patent: 3766104 (1973-10-01), Bonin et al.
patent: 3796634 (1974-03-01), Haynes et al.
patent: 3810781 (1974-05-01), Eriksson et al.
patent: 3826678 (1974-07-01), Hoffman et al.
patent: 3846353 (1974-11-01), Grotta
patent: 3853804 (1974-12-01), Yen et al.
patent: 3947352 (1976-03-01), Cuatrecasas et al.
patent: 4001583 (1977-01-01), Barrett
patent: 4046725 (1977-09-01), Pusineri
patent: 4048064 (1977-09-01), Clark, III
patent: 4085019 (1978-04-01), Green
patent: 4102746 (1978-07-01), Goldberg
patent: 4116898 (1978-09-01), Dudley et al.
patent: 4118485 (1978-10-01), Eriksson et al.
patent: 4141857 (1979-02-01), Levy et al.
patent: 4217338 (1980-08-01), Quash
patent: 4229838 (1980-10-01), Mano
patent: 4239664 (1980-12-01), Teng et al.
patent: 4265827 (1981-05-01), Sabacky
patent: 4265927 (1981-05-01), Ericksson et al.
patent: 4268423 (1981-05-01), Rohrbach et al.
patent: 4301067 (1981-11-01), Koshugi
patent: 4326532 (1982-04-01), Hammar
patent: 4329383 (1982-05-01), Joh
patent: 4331697 (1982-05-01), Kudo et al.
patent: 4349467 (1982-09-01), Williams et al.
patent: 4350806 (1982-09-01), Wagener
patent: 4369256 (1993-01-01), Casu et al.
patent: 4424346 (1984-01-01), Hall et al.
patent: 4521564 (1985-06-01), Solomon et al.
patent: 4526714 (1985-07-01), Feijen et al.
patent: 4565740 (1986-01-01), Golander et al.
patent: 4600652 (1986-07-01), Solomon et al.
patent: 4613517 (1986-09-01), Williams et al.
patent: 4613665 (1986-09-01), Larm
patent: 4642242 (1987-02-01), Solomon et al.
patent: 4720512 (1988-01-01), Hu et al.
patent: 4737544 (1988-04-01), McCain et al.
patent: 4786556 (1988-11-01), Hu et al.
patent: 4800016 (1989-01-01), Yang
patent: 4806595 (1989-02-01), Noishiki et al.
patent: 4810784 (1989-03-01), Larm
patent: 4863611 (1989-09-01), Bernstein et al.
patent: 4865870 (1989-09-01), Hu et al.
patent: 4871357 (1989-10-01), Hsu et al.
patent: 4876126 (1989-10-01), Takemura et al.
patent: 4935204 (1990-06-01), Seidel et al.
patent: 4944767 (1990-07-01), Barbucci et al.
patent: 4987181 (1991-01-01), Bichon et al.
patent: 5000854 (1991-03-01), Yang
patent: 5013717 (1991-05-01), Solomon et al.
patent: 5047020 (1991-09-01), Hsu
patent: 5049403 (1991-09-01), Larm et al.
patent: 5053048 (1991-10-01), Pinchuk
patent: 5061750 (1991-10-01), Feijen et al.
patent: 5116962 (1992-05-01), Stuber et al.
patent: 5132108 (1992-07-01), Narayanan et al.
patent: 5145956 (1992-09-01), Lam et al.
patent: 5151192 (1992-09-01), Matkovich et al.
patent: 5159050 (1992-10-01), Onwumere
patent: 5165919 (1992-11-01), Sasaki et al.
patent: 5182317 (1993-01-01), Winters et al.
patent: 5198493 (1993-03-01), Holmberg et al.
patent: 5211850 (1993-05-01), Shettigar et al.
patent: 5213898 (1993-05-01), Larm et al.
patent: 5217492 (1993-06-01), Guire et al.
patent: 5219926 (1993-06-01), Lindman et al.
patent: 5240994 (1993-08-01), Brink et al.
patent: 5250613 (1993-10-01), Bergstrom et al.
patent: 5258041 (1993-11-01), Guire et al.
patent: 5308641 (1994-05-01), Cahalan et al.
patent: 5350800 (1994-09-01), Verhoeven et al.
patent: 5391580 (1995-02-01), Douglas et al.
patent: 5415938 (1995-05-01), Cahalan et al.
patent: 5416198 (1995-05-01), Anderson et al.
patent: 5476715 (1995-12-01), Otto
patent: 5532311 (1996-07-01), Sirvio et al.
patent: 5607475 (1997-03-01), Cahalan et al.
patent: 1160548 (1984-01-01), None
patent: 276 814 A1 (1990-03-01), None
patent: 0 281 128 A1 (1988-09-01), None
patent: 295905B1 (1988-12-01), None
patent: 0466178A1 (1992-01-01), None
patent: 2 041 377 (1980-09-01), None
patent: 88/02623 (1988-04-01), None
patent: 91/16932 (1991-11-01), None
patent: 92/00747 (1992-01-01), None
patent:
Sirvio Lary M.
Wirt David F.
Burns Doane , Swecker, Mathis LLP
Kulkosky Peter F.
Terumo Cardiovascular Systems Corporation
LandOfFree
Removal of biologically active agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Removal of biologically active agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Removal of biologically active agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2480433